By Marie Rosenthal
SAN FRANCISCO—Adults with HIV who were switched to the once-daily, fixed-dose combination tablet of doravirine (DOR), lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) (Delstrigo, Merck) demonstrated virologic suppression for at least six months on a stable antiretroviral treatment regimen, according to a new study.
DRIVE-SHIFT is a phase 3 multicenter, open-label, randomized, active-controlled, noninferiority clinical trial evaluating a switch to DOR/3TC/TDF